Press releases
- Aurinia to Participate in Upcoming Investor Healthcare Conferences
- Aurinia Announces 2024 Annual General Meeting Results
- Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
- Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
- Aurinia Provides Update on Proxy Statement
- Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf
- Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
- Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
- Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
- Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 16.87 |
Average volume | -- |
---|---|
Shares outstanding | 143.02m |
Free float | 132.91m |
P/E (TTM) | -- |
Market cap | 802.34m USD |
EPS (TTM) | -0.4363 USD |
Data delayed at least 20 minutes, as of Nov 09 2021.
More ▼